KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Common Equity: 2009-2024

Historic Common Equity for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $5.4 billion.

  • Teva Pharmaceutical Industries' Common Equity rose 13.65% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 13.65%. This contributed to the annual value of $5.4 billion for FY2024, which is 33.79% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Common Equity is $5.4 billion, which was down 33.79% from $8.1 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Common Equity ranged from a high of $11.2 billion in FY2021 and a low of $5.4 billion during FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Common Equity averaged around $7.4 billion, with its median value being $8.1 billion (2023).
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Common Equity rose by 1.65% in 2021 and then plummeted by 33.79% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Common Equity (Yearly) stood at $11.1 billion in 2020, then grew by 1.65% to $11.2 billion in 2021, then declined by 23.53% to $8.6 billion in 2022, then decreased by 5.49% to $8.1 billion in 2023, then tumbled by 33.79% to $5.4 billion in 2024.